ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-0-0-09815 10.3892/etm.2021.9815 Articles MicroRNA-497-5p downregulation inhibits cell viability, reduces extracellular matrix deposition and induces apoptosis in human hyperplastic scar fibroblasts by regulating Smad7 LiZhiqiang WangPengtao ZhangJie ZhaoDongkui Shanghai Meizhizhen Medical Cosmetology Clinic, Shanghai 200122, P.R. China Correspondence to: Mr. Zhiqiang Li, Shanghai Meizhizhen Medical Cosmetology Clinic, 898 Puming Road, Pudong, Shanghai 200122, P.R. China ll11112345@163.com 04 2021 23 02 2021 21 4 384 13 02 2020 07 07 2020 Copyright: © Li et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Hypertrophic scars (HSs) are characterized by excessive extracellular matrix deposition and excessive growth of dense fibrous tissues. MicroRNAs (miRNAs/miRs) serve key roles in HS formation. The present study investigated the expression, role and mechanism underlying the effects of miR-497-5p in HS formation. miR-497-5p expression was detected via reverse transcription-quantitative PCR. The association between miR-497-5p and Smad7 was analyzed using TargetScan and luciferase reporter assays. Protein expression levels of extracellular matrix markers were measured via western blotting. Cell viability and apoptosis were determined using the Cell Counting Kit-8 assay and flow cytometry, respectively. The results suggested that miR-497-5p expression was upregulated in HS tissues and human HS fibroblasts (hHSFs) compared with healthy control skin tissues and CCC-ESF-1 cells, respectively. Smad7 was directly targeted by miR-497-5p, and was downregulated in HS tissues and hHSFs compared with healthy control skin tissues and CCC-ESF-1 cells, respectively. Moreover, Smad7 upregulation significantly inhibited cell viability, decreased extracellular matrix deposition and induced apoptosis in hHSFs compared with the control-plasmid group. Moreover, the results indicated that, compared with the inhibitor control group, miR-497-5p inhibitor inhibited cell viability, decreased extracellular matrix deposition and induced apoptosis in hHSFs, which were significantly reversed by Smad7 knockdown. In conclusion, the results indicated that miR-497-5p downregulation repressed HS formation by inhibiting extracellular matrix deposition and hHSF proliferation at least partly by targeting Smad7.

 hypertrophic scar extracellular matrix microR-497-5p Smad7 fibroblasts Funding: No funding was received. Introduction

Hypertrophic scars (HS) caused by various traumas are a product of the healing process and seriously affect the patient's physical health (1-3). HS is characterized by hyperproliferation of scar fibroblasts and excessive accumulation of extracellular matrix (ECM) (4,5). At present, the main treatment strategy for HS is surgical excision with superficial X-ray radiation and dot-array laser (6); however, surgical treatment may cause secondary injuries (7), and radiation therapy can cause radiation dermatitis, delayed incision healing and skin canceration at the irradiation site (6,7). Therefore, identifying the molecular mechanisms underlying HS formation to aid with the development of novel therapeutic strategies for HS is important.

MicroRNAs (miRNAs/miRs) are endogenous, non-coding, single-stranded small RNAs, which regulate gene and protein expression at the post-transcriptional level by binding to target genes in a complementary or incompletely complementary manner (8). Evidence has indicated that miRNAs serve key roles in pathophysiological processes, such as cell proliferation, apoptosis, organ development and immune regulation (8-12). Increasing evidence has also suggested that miRNAs serve a critical role in HS formation (13-16). miR-497-5p has been reported to serve critical roles in various types of cancer via regulating cell proliferation and apoptosis, and modulating the expression of several genes and proteins (17-20). In addition, the important roles of miR-497-5p in myofibroblast differentiation and pulmonary fibrogenesis have been reported (21). The aforementioned studies indicated that miR-497-5p may serve an important role in the occurrence and development of HS. However, the role of miR-497-5p in HS formation is not completely understood.

Smad7 serves as a negative regulator of transforming growth factor (TGF)-β signaling via multiple mechanisms, such as TGF-β type I receptor degradation induction, Smad2/3 phosphorylation and recruitment blocking (22,23). Smad7 can protect against TGF-β-induced fibrosis in various organs, including the lungs, kidneys and liver (24,25). Several studies have reported an important role of Smad7 in the regulation of fibroblast proliferation and ECM accumulation (26-28), indicating an important role for Smad7 in HS formation.

The aim of the present study was to investigate the expression and role of miR-497-5p in HS formation, and to further explore the underlying molecular mechanism.

 Materials and methods <sec> <title>Clinical samples

A total of 22 HS tissues (age 27-59 years; 11 male patients and 11 female patients) were collected during scar excision at Shanghai Meizhen Medical Cosmetology Clinic. Additionally, 22 healthy control skin tissues (age, 24-63 years; 11 male patients and 11 female patients) were collected during auto-skin grafting at Shanghai Meizhen Medical Cosmetology Clinic between May 23, 2017 and June 4, 2019. Written informed consent was obtained from the patients and all patients approved the use of their samples in the present study. The present study was approved by the Ethics Committee of Shanghai Meizhizhen Medical Cosmetology Clinic.

 Cell culture and cell transfection

Human embryonic skin fibroblasts CCC-ESF-1 (cat. no. YB-ATCC-3084; Shanghai Zibo Biological Technology Co., Ltd.) and human HS fibroblasts (hHSFs; cat. no. C0618; Shanghai Guandao Biological engineering Co., Ltd.) were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C with 5% CO2.

Control-plasmid (1 µg; cat. no. sc-437275; Santa Cruz Biotechnology, Inc.), Smad7-plasmid (1 µg; cat. no. sc-400251-ACT; Santa Cruz Biotechnology, Inc.), miR-497-5p inhibitor (100 nM; 5'-ACAAACCACAGTGTGCTGCTG-3'; Sangon Biotech Co., Ltd.), inhibitor control (100 nM; 5'-CAGTACTTTTGTGTAGTACAA-3'; Sangon Biotech Co., Ltd.), Smad7-short hairpin (sh)RNA (1 µg; cat. no. sc-36508-SH; Santa Cruz Biotechnology, Inc.), control-shRNA (1 µg; cat. no. sc-108060; Santa Cruz Biotechnology, Inc.) or 100 nM miR-497-5p inhibitor + 1 µg Smad7-shRNA were transfected into hHSFs (5x104 per well) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. At 48 h post-transfection, transfection efficiency was assessed via reverse transcription-quantitative PCR (RT-qPCR).

 Luciferase reporter analysis

The binding sites between miR-497-5p and Smad7 were predicted by TargetScan version 7.2 (www.targetscan.org/vert_72). To confirm the binding sites between miR-497-5p and Smad7, a dual-luciferase reporter assay was conducted. Briefly, the wild-type (WT-Smad7) and mutant (MUT-Smad7) 3'-untranslated region (UTR) of Smad7 were cloned into a pmiR-RB-Report™ dual luciferase reporter gene plasmid vector (Guangzhou RiboBio Co., Ltd.) according to the manufacturer's instructions. hHSFs (5x104 per well) were co-transfected with 1 ng WT-Smad7 or 1 ng MUT-Smad7 and 50 nM miR-497-5p mimic (5'-CAGCAGCACACUGUGGUUUGUAAACCACAGUGUGCUGCUGUU-3'; Guangzhou RiboBio Co., Ltd.) or 50 nM mimic control (5'-UUCUCCGAACGUGUCACGUTT-3'; Guangzhou RiboBio Co., Ltd.) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Renilla luciferase pRL-TK vector (Promega Corporation) was used as the internal control. At 48 h post-transfection, relative luciferase activities were assessed using the Dual-Luciferase Reporter Assay system (Promega Corporation). Firefly luciferase activity was normalized to Renilla luciferase activity.

 Cell Counting Kit-8 (CCK-8) assay

The CCK-8 assay (Beyotime Institute of Biotechnology) was performed to assess hHSF cell viability according to the manufacturer's protocol. hHSFs seeded (1x104 cells/well) into 96-well plates were transfected with 1 µg control-plasmid, 1 µg Smad7-plasmid, 100 nM miR-497-5p inhibitor, 100 nM inhibitor control or 100 nM miR-497-5p inhibitor + 1 µg Smad7-shRNA. At 48 h post-transfection, 10 µl CCK-8 solution was added to each well and incubated at 37˚C with 5% CO2 for 4 h. Subsequently, hHSF cell viability was assessed by measuring the absorbance at a wavelength of 490 nm using a microplate reader.

 Flow cytometry assay

At 48 h post-transfection, hHSF apoptosis was assessed using the Annexin V-FITC/PI apoptosis detection kit (Beyotime Institute of Biotechnology) according to the manufacturer's instructions. FACScan flow cytometer (Beckman Coulter, Inc.) was used to detect early and late hHSF apoptosis. Data were analyzed using FlowJo software version 7.6.1 (FlowJo LLC).

 RT-qPCR

Total RNA was extracted from tissues or cells using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Total RNA was reverse transcribed into cDNA using the miScript Reverse Transcription kit (Qiagen GmbH) according to the manufacturer's instructions. The conditions for reverse transcription were as follows: 70˚C for 5 min, 37˚C for 5 min and 42˚C for 60 min. Subsequently, qPCR was performed using the QuantiFast SYBR Green PCR kit (Qiagen GmbH). The following thermocycling conditions were used for qPCR: Initial denaturation at 95˚C for 10 min; followed by 35 cycles of 15 sec at 95˚C, 40 sec at 55˚C and a final extension step at 72˚C for 30 sec. miRNA and mRNA expression levels were quantified using the 2-ΔΔCq method (29) and normalized to the internal reference genes U6 and GAPDH, respectively. The primer sequences used for PCR were as follows: GAPDH forward, 5'-TGTTGCCATCAATGACCCCTT-3' and reverse, 5'-CTCCACGACGTACTCAGCG-3'; Smad7 forward, 5'-GCTCCCATCCTGTGTGTTAA-3' and reverse, 5'-TAGGTGTCAGCCTAGGATGGT-3'; U6 forward, 5'-GCTTCGGCAGCACATATACTAAAAT-3' and reverse, 5'-CGCTTCACGAATTTGCGTGTCAT-3'; miR-497-5p forward, 5'-ATCCAGTGCGTGTCGTG-3' and reverse, 5'-TGCTCAGCAGCACACTGT-3'.

 Western blotting

Total protein was extracted from tissues or cells using RIPA lysis buffer (Beyotime Institute of Biotechnology). A bicinchoninic acid assay kit (Thermo Fisher Scientific, Inc.) was used to measure protein concentrations. Proteins (40 µg/lane) were separated via 12% SDS-PAGE gel and electrically transferred onto PVDF membranes. After blocking with 5% skim milk at room temperature for 1.5 h, the membranes were incubated at 4˚C overnight with primary antibodies targeted against: Smad7 (1:1,000; cat. no. ab227309; Abcam), α-smooth muscle actin (α-SMA; 1:1,000; cat. no. ab32575; Abcam), type I collagen (Col I; 1:1,000; cat. no. ab34710; Abcam), type III collagen (Col III; 1:1,000; cat. no. ab7778; Abcam) and GAPDH (1:1,000; cat. no. ab9485; Abcam). Subsequently, the membranes were incubated with an anti-rabbit horseradish peroxidase-conjugated IgG secondary antibody (cat. no. 7074; 1:2,000; Cell Signaling Technology, Inc.) at room temperature for 2 h. Protein bands were visualized using an enhanced chemiluminescence detection system (Thermo Fisher Scientific, Inc.). ImageJ version 2.0 software (National Institutes of Health) was used to quantify band intensities.

 Statistical analysis

Data are presented as the mean ± SD of three independent experiments. Statistical analyses were performed using SPSS software (version 18.0; SPSS, Inc.). Comparisons between two groups were analyzed using the Student's t-test. Comparisons among multiple groups were analyzed using one-way ANOVA followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>miR-497-5p is upregulated in HS tissues and hHSFs

miR-497-5p expression levels in 22 HS tissues, 22 healthy control skin tissues, human embryonic skin fibroblasts CCC-ESF-1 and hHSFs were determined via RT-qPCR. The results indicated that the expression levels of miR-497-5p were significantly upregulated in HS tissues compared with healthy control skin tissues (Fig. 1A). Similarly, the expression level of miR-497-5p in hHSFs was significantly higher compared with CCC-ESF-1 cells (Fig. 1B). The results indicated that miR-497-5p may be involved in the development of HS.

 Smad7 is a target gene of miR-497-5p

TargetScan was used to predict the potential targets of miR-497-5p, which indicated a binding site between miR-497-5p and the 3'UTR of Smad7 mRNA (Fig. 2A). Subsequently, a dual-luciferase reporter assay was conducted to assess the binding site between miR-497-5p and the 3'UTR of Smad7 (Fig. 2B). Compared with cells co-transfected with mimic control and Smad7-WT, the luciferase activity of cells co-transfected with miR-497-5p mimic and Smad7-WT was significantly reduced. By contrast, there was no significant difference between the luciferase activity of cells co-transfected with mimic control and Smad7-MUT, and cells co-transfected with miR-497-5p mimic and Smad7-MUT. The results indicated that Smad7 may be a direct target gene of miR-497-5p.

Furthermore, compared with healthy control skin tissues and CCC-ESF-1 cells, the mRNA and protein expression levels of Smad7 were significantly downregulated in HS tissues and hHSFs, respectively (Fig. 2C-F).

 Effect of Smad7 on hHSFs

The effect of Smad7 was investigated in hHSFs. hHSFs were transfected with control-plasmid or Smad7-plasmid for 48 h. Compared with the control-plasmid group, Smad7-plasmid significantly increased Smad7 mRNA and protein expression levels in hHSFs (Fig. 3A and B). In addition, compared with the control-plasmid group, Smad7-plasmid significantly decreased cell viability, enhanced apoptosis, and inhibited the protein expression of Col I, Col III and α-SMA in hHSFs (Fig. 3C-I).

 Effect of miR-497-5p on hHSF viability and apoptosis

The effect of miR-497-5p on hHSF viability and apoptosis was analyzed. Compared with the inhibitor control group, miR-497-5p inhibitor significantly inhibited miR-497-5p expression in hHSFs (Fig. 4A). Smad7-shRNA notably decreased the mRNA and protein expression levels of Smad7 in hHSFs compared with the control-shRNA group (Fig. 4B and C). miR-497-5p inhibitor-mediated reduction in hHSF viability and induction of apoptosis were reversed by co-transfection with Smad7-shRNA (Fig. 4D-F).

 Effect of miR-497-5p on the protein expression of Smad7, Col I, Col III and α-SMA in hHSFs

The effect of miR-497-5p on extracellular matrix deposition in hHSFs was investigated. At 48 h post-transfection, the expression of Smad7, Col I, Col III and α-SMA in hHSFs was assessed. The results indicated that miR-497-5p inhibitor markedly increased the mRNA and protein expression levels of Smad7 in hHSFs compared with the inhibitor control group (Fig. 5A and B), which was reversed by co-transfection with Smad7-shRNA. Moreover, the results indicated that miR-497-5p inhibitor significantly decreased the protein expression levels of Col I, Col III and α-SMA in hHSFs compared with the inhibitor control group, which was reversed by co-transfection with Smad7-shRNA (Fig. 5C-F).

 Discussion

The present study demonstrated that miR-497-5p was upregulated in HS tissues and hHSFs compared with healthy control skin tissues and CCC-ESF-1 cells, respectively. Smad7 was a direct target of miR-497-5p, and was downregulated in HS tissues and hHSFs compared with healthy control skin tissues and CCC-ESF-1 cells, respectively. miR-497-5p downregulation significantly inhibited ECM deposition, inhibited hHSF proliferation and induced cell apoptosis compared with the inhibitor-control group, which were all reversed by Smad7 downregulation. Collectively, the results of the present study may aid with the development of novel therapeutic strategies for HS.

To date, HS has been the focus of research on trauma and plastic surgery (30). miRNAs have been identified to serve critical roles in the progression of skin wound repair and skin diseases (31,32). Research on miRNAs in HS has attracted increasing attention (33-38). miR-497-5p, which has been reported to serve critical roles in the regulation of cell proliferation and apoptosis (17-21), was investigated in the present study.

The level of miR-497-5p was detected in HS tissues, healthy control skin tissues, human embryonic skin fibroblasts CCC-ESF-1 and hHSFs via RT-qPCR. The results suggested that miR-497-5p was highly expressed in HS tissues and hHSFs compared with healthy control skin tissues and CCC-ESF-1 cells, respectively, and Smad7 was identified as a direct target of miR-497-5p. Consistent with a previous study (39), the present study indicated that Smad7 was downregulated in HS tissues and hHSFs compared with healthy control skin tissues and CCC-ESF-1 cells, respectively. The results suggested that miR-497-5p might participate in HS formation by regulating the expression of Smad7. HS is characterized by abnormal fibroblast proliferation, and collagen and ECM deposition (4,5). Zhang et al (35) reported that miR-137 inhibits HS fibroblast proliferation and metastasis via targeting pleiotrophin. Wu et al (36) suggested that miR-155 inhibits the formation of HSs by inhibiting HS fibroblast proliferation and collagen expression by targeting hypoxia inducible factor-1α via the PI3K/AKT signaling pathway. Zhou et al (37) indicated that miR-519d inhibits proliferation and induces apoptosis of human HS fibroblasts, serving a critical role in HS formation. Moreover, previous studies have reported that Smad7 serves a key role in the regulation of fibroblast growth and ECM accumulation (26-28). Therefore, the present study investigated the effect of Smad7 on ECM secretion, and hHSF proliferation and apoptosis. The results indicated that Smad7 upregulation significantly inhibited cell viability, induced cell apoptosis, and decreased the protein expression levels of Col I, Col III and α-SMA in hHSFs compared with the control-plasmid group. miRNAs work by negatively regulating the expression of target genes (40,41). Using bioinformatics software, Smad7 was identified as a potential target gene of miR-497-5p in the present study. Therefore, it was hypothesized that miR-497-5p may regulate scar fibroblast proliferation and ECM production by regulating the expression of Smad7, thereby serving a role in HS formation. As expected, the results of the present study indicated that miR-497-5p inhibition decreased cell viability, induced apoptosis, and decreased the protein expression levels of Col I, Col III and α-SMA in hHSFs compared with the inhibitor control group. Notably, miR-497-5p knockdown-mediated effects on hHSFs were eliminated by Smad7 downregulation. However, in the present study, only the CCK-8 assay was performed to assess the effect of miR-497-5p/Smad7 on hHSF viability, which was a limitation. Future studies should perform EdU staining to investigate the effect of miR-497-5p/Smad7 on hHSF proliferation.

In summary, the present study indicated that miR-497-5p was upregulated in HS. miR-497-5p downregulation inhibited HS formation by inhibiting ECM deposition, preventing hHSF proliferation at least partly by targeting Smad7. Therefore, the miR-497-5p/Smad7 axis may serve as a promising therapeutic target for the treatment of HS. However, the present study was only a preliminary study of the effect of miR-497-5p on hHSFs and further investigation is required. For example, the effects of miR-497-5p/Smad7 on hHSF migration and the role of the miR-497-5p/Smad7 axis in HSs in vivo require further investigation. Moreover, whether there is a correlation between the expression of miR-497-5p/Smad7 and the clinicopathological parameters of patients with HS should be investigated in the future.

 Acknowledgements

Not applicable.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

ZL designed the study, collected, analyzed and interpreted the data and prepared the manuscript. PW, JZ and DZ collected the data and performed statistical analysis. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Shanghai Meizhizhen Medical Cosmetology Clinic. Written informed consent was obtained from the patients and all patients approved the use of their samples in the present study.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References GabrielVHypertrophic scarPhys Med Rehabil Clin N Am2230131020112162472210.1016/j.pmr.2011.02.002 FanSQCaiJLQinLYWangZHLiuZZSunMLEffect of heparin on production of transforming growth factor (TGF)-betal and TGF-betal mRNA expression by human normal skin and hyperplastic scar fibroblastsAnn Plast Surg6029930520081844351310.1097/SAP.0b013e318061d310 GauglitzGGKortingHCPavicicTRuzickaTJeschkeMGHypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategiesMol Med1711312520112092748610.2119/molmed.2009.00153 SidgwickGPIqbalSABayatAAltered expression of hyaluronan synthase and hyaluronidase mRNA may affect hyaluronic acid distribution in keloid disease compared with normal skinExp Dermatol2237737920132361475210.1111/exd.12147 SyedFAhmadiEIqbalSASinghSMcGroutherDABayatAFibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: Clinical implications for lesional site-directed therapyBr J Dermatol164839620112084951610.1111/j.1365-2133.2010.10048.x ZuccaroJZiolkowskiNFishJA systematic review of the effectiveness of laser therapy for hypertrophic burn scarsClin Plast Surg4476777920172888830210.1016/j.cps.2017.05.008 XuXLaiLZhangXChenJChenJWangFZhengJChenMAutologous chyle fat grafting for the treatment of hypertrophic scars and scar-related conditionsStem Cell Res Ther96420182952318110.1186/s13287-018-0782-8 BartelDPMicroRNAs: Genomics, biogenesis, mechanism, and functionCell11628129720041474443810.1016/s0092-8674(04)00045-5 EbertMSSharpPARoles for microRNAs in conferring robustness to biological processesCell14951552420122254142610.1016/j.cell.2012.04.005 RogersKChenXBiogenesis, turnover, and mode of action of plant microRNAsPlant Cell252383239920132388141210.1105/tpc.113.113159 HayesJPeruzziPPLawlerSMicroRNAs in cancer: Biomarkers, functions and therapyTrends Mol Med2046046920142502797210.1016/j.molmed.2014.06.005 WojtasBFerrazCStokowyTHauptmannSLangeDDralleHMusholtTJarzabBPaschkeREszlingerMDifferential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomasMol Cell Endocrinol3881920142463148010.1016/j.mce.2014.02.011 MuSKangBZengWSunYYangFMicroRNA-143-3p inhibits hyperplastic scar formation by targeting connective tissue growth factor CTGF/CCN2 via the Akt/mTOR pathwayMol Cell Biochem4169910820162707546710.1007/s11010-016-2699-9 HaoXZFanHMIdentification of miRNAs as atherosclerosis biomarkers and functional role of miR-126 in atherosclerosis progression through MAPK signalling pathwayEur Rev Med Pharmacol Sci2127252733201728678312 BiSChaiLYuanXCaoCLiSMicroRNA-98 inhibits the cell proliferation of human hypertrophic scar fibroblasts via targeting Col1A1Biol Res502220172862944410.1186/s40659-017-0127-6 ZhuHYLiCBaiWDSuLLLiuJQLiYShiJHCaiWXBaiXZJiaYHMicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblastsPLoS One9e9711420142481701110.1371/journal.pone.0097114 QuFYeJPanXWangJGanSChuCChuJZhangXLiuMHeHCuiXMicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinomaJ Drug Target27677420193018347810.1080/1061186X.2018.1479755 ChaiLKangXJSunZZZengMFYuSRDingYLiangJQLiTTZhaoJMiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cellsCancer Manag Res10989100320182976056710.2147/CMAR.S163335 SunZLiAYuZLiXGuoXChenRMicroRNA-497-5p suppresses tumor cell growth of osteosarcoma by targeting ADP ribosylation factor-like protein 2Cancer Biother Radiopharm3237137820172926591910.1089/cbr.2017.2268 ChenYKuangDZhaoXChenDWangXYangQWanJZhuYWangYZhangSmiR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcomaOncotarget7581485816120162753190010.18632/oncotarget.11252 ChenXShiCWangCLiuWChuYXiangZHuKDongPHanXThe role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesisSci Rep74095820172809821810.1038/srep40958 NakaoAAfrakhteMMorénANakayamaTChristianJLHeuchelRItohSKawabataMHeldinNEHeldinCHten DijkePIdentification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signallingNature3896316351997933550710.1038/39369 KavsakPRasmussenRKCausingCGBonniSZhuHThomsenGHWranaJLSmad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradationMol Cell61365137520001116321010.1016/s1097-2765(00)00134-9 YeungMLYaoYJiaLChanJFWChanKHCheungKFChenHPoonVKMTsangAKLToKKWMERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2Nat Microbiol11600420162757216810.1038/nmicrobiol.2016.4 LiuJKongDQiuJXieYLuZZhouCLiuXZhangRWangYPraziquantel ameliorates CCl4-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cellsBr J Pharmacol1764666468020193141213710.1111/bph.14831 ZhouRWangCWenCWangDmiR-21 promotes collagen production in keloid via Smad7Burns4355556120172771761810.1016/j.burns.2016.09.013 ChenZLiuYXiaoMXiaoHQiuWZhaoYEffects of over-expressing smad7 gene on keloid fibroblastsZhongguo Xiu Fu Chong Jian Wai Ke Za Zhi3087187520162978632510.7507/1002-1892.20160177(In Chinese) TaoJWangJLiCWangWYuHLiuJKongXChenYMiR-216a accelerates proliferation and fibrogenesis via targeting PTEN and SMAD7 in human cardiac fibroblastsCardiovasc Diagn Ther953554420193203894310.21037/cdt.2019.11.06 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods2540240820011184660910.1006/meth.2001.1262 LeeHJJangYJRecent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloidsInt J Mol Sci1971120182949863010.3390/ijms19030711 AberdamDCandiEKnightRKMelinoGmiRNAs, ‘sternness’ and skinTrends Biochem Sci3358359120081884845210.1016/j.tibs.2008.09.002 BotchkarevaNVMicroRNA/mRNA regulatory networks in the control of skin development and regenerationCell Cycle1146847420122226218610.4161/cc.11.3.19058 ChenLLiJLiQYanHZhouBGaoYLiJNon-coding RNAs: The new insight on hypertrophic scarJ Cell Biochem1181965196820172806742610.1002/jcb.25873 TsaiCHOgawaRKeloid research: Current status and future directionsScars Burn Heal5205951311986865920193145295710.1177/2059513119868659 ZhangQGuoBHuiQChangPTaoKmiR-137 inhibits proliferation and metastasis of hypertrophic scar fibroblasts via targeting pleiotrophinCell Physiol Biochem4998599520183018453010.1159/000493236 WuXLiJYangXBaiXShiJGaoJLiYHanSZhangYHanFmiR-155 inhibits the formation of hypertrophic scar fibroblasts by targeting HIF-1α via PI3K/AKT pathwayJ Mol Histol4937738720182978548810.1007/s10735-018-9778-z ZhouXXieYXiaoHDengXWangYJiangLLiuCZhouRMicroRNA-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7Biomed Pharmacother10018419020182942866610.1016/j.biopha.2018.01.158 WangXZhangYJiangBHZhangQZhouRPZhangLWangCStudy on the role of Hsa-miR-31-5p in hypertrophic scar formation and the mechanismExp Cell Res36120120920172905652110.1016/j.yexcr.2017.09.009 ZunwenLShizhenZDewuLYunguiMPuNEffect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitroBurns3840441320122192579410.1016/j.burns.2011.08.013 LiuBLiJCairnsMJIdentifying miRNAs, targets and functionsBrief Bioinform1511920142317568010.1093/bib/bbs075 LuTXRothenbergMEMicroRNAJ Allergy Clin Immunol1411202120720182907445410.1016/j.jaci.2017.08.034

miR-497-5p expression is upregulated in HS tissues and cells. Relative miR-497-5p expression levels in (A) HS tissue, healthy tissue, (B) CCC-ESF-1 cells and hHSFs. **P<0.01 vs. healthy tissues; &&P<0.01 vs. CCC-ESF-1. miR, micro RNA; HS, hypertrophic scar; hHSFs, human hyperplastic scar fibroblasts.

Smad7 is a target gene of miR-497-5p. (A) The binding sites between miR-497-5p and the 3'-UTR of Smad7 were predicted using TargetScan. (B) Luciferase activity was measured by performing a dual-luciferase reporter assay. Smad7 mRNA and protein expression levels in (C and D) HS tissues, healthy tissues, (E and F) CCC-ESF-1 cells and hHSFs. **P<0.01 vs. mimic control; ##P<0.01 vs. healthy tissues; &&P<0.01 vs. CCC-ESF-1. miR, micro RNA; 3'-UTR, 3'-untranslated region; HS, hypertrophic scar; WT, wild-type; MUT, mutant.

Effect of Smad7 on hHSFs. hHSFs were transfected with control-plasmid or Smad7-plasmid for 48 h. (A) Protein and (B) mRNA expression levels of Smad7. (C) Cell viability was assessed by performing the Cell Counting Kit-8 assay. Cell apoptosis was (D) determined by flow cytometry and (E) quantified. Protein expression levels were (F) determined by western blotting and semi-quantified for (G) Col I, (H) Col III and (I) α-SMA. **P<0.01 vs. control-plasmid. hHSFs, human hyperplastic scar fibroblasts; Col I, type I collagen; Col III, type III collagen; α-SMA, α-smooth muscle actin.

Effect of miR-497-5p inhibitor on hHSF viability and apoptosis. (A) miR-497-5p expression levels in hHSFs transfected with inhibitor control or miR-497-5p inhibitor for 48 h. (B) Protein and (C) mRNA expression levels of Smad7 in hHSFs transfected with control-shRNA or Smad7-shRNA for 48 h. hHSFs were transfected with inhibitor control, miR-497-5p inhibitor, miR-497-5p inhibitor + control-shRNA or miR-497-5p inhibitor + Smad7-shRNA for 48 h. (D) The Cell Counting Kit-8 assay was performed to determine hHSF viability. Cell apoptosis was (E) determined by flow cytometry and (F) quantified. **P<0.01 vs. inhibitor control; ##P<0.01 vs. control-shRNA; &&P<0.01 vs. miR-497-5p inhibitor + control-shRNA. miR, micro RNA; hHSF, human hyperplastic scar fibroblast; shRNA, short hairpin RNA.

Effect of miR-497-5p inhibitor on Smad7, Col I, Col III and α-SMA expression in hHSFs. hHSFs were transfected with control-shRNA, Smad7-shRNA, inhibitor control, miR-497-5p inhibitor, miR-497-5p inhibitor + control-shRNA or miR-497-5p inhibitor + Smad7-shRNA for 48 h. (A) Protein and (B) mRNA expression levels of Smad7. Protein expression levels were (C) determined by western blotting and semi-quantified for (D) Col I, (E) Col III and (F) α-SMA. **P<0.01 vs. inhibitor control &&P<0.01 vs. miR-497-5p inhibitor + control-shRNA. miR, microRNA; Col I, type I collagen; Col III, type III collagen; α-SMA, α-smooth muscle actin; hHSFs, human hyperplastic scar fibroblasts; shRNA, short hairpin RNA.